Biogen (BIIB) Stock News

JPMorgan upgraded Biogen to overweight from neutral. Analysts see a promising path with key data next year for felzartamab and litifilimab. Biogen is up 3.6% premarket.

JP Morgan raised its rating on Biogen (BIIB) to Overweight from Neutral and set a $300 price target.

JP Morgan raised Biogen to Overweight from Neutral, citing a more positive outlook.

UBS increased its price target for Biogen from $240.00 to $270.00.

RBC Capital reduced its price target for Biogen from $260.00 to $256.00.

Biogen reported 52-week Phase 2 data from the AMETHYST study of litifilimab in cutaneous lupus erythematosus. At Week 52, 27.2% of patients on litifilimab from the start achieved clear or almost clear skin, up from 19.0% at Week 24. Patients switching from placebo saw rapid onset within four weeks, with 33.7% reaching clear or almost clear skin by Week 52. Safety was consistent with prior studies.